In patients with HIV infection, early linkage to and retention in continuous HIV medical care are the most important components of care shown to improve health outcomes in this population.1 In the United States, approximately 7
A once daily MVC plus DRV/r regimen had an effective role in antiretroviral drug-pretreated individuals with controlled HIV infection in this trial. In an aging HIV-infected population, with increasing comorbidities, this combination could be a safer option than standard triple therapy. More here.
It now seems probable that most people with HCV infection can be cured—even if they are co-infected with HIV. But the "cost" of cure is expensive. This author concludes that many new regimens are cost effective and should not be withheld or made difficult to obtain by insurance companies and other payors.
A statistically significant association exists between efavirenz for initial HIV therapy and the risk suicidality. When this drug is given as a component of an antiretroviral drug regimen, patients should be monitored carefully for the possibility of deterioration of their depression or evidence of suicidal behavior.